Interleukin-6 Receptor Antagonist Approved by FDA Based on Retrospective Case Reports for the Treatment of Steroid-Refractory Cytokine Release Syndrome Induced by a Different Cause, CAR T Cell Therapy , in 2017.
Kipinzani cha vipokezi vya interleukin-6 kiliidhinishwa na FDA kwa sababu ya utafiti wa baadaye wa matibabu ya ugonjwa wa ongezeko kupita kiasi la sitokini uliosababishwa na sababu tofauti, matibabu ya seli ya CAR, mwaka wa 2017.